Optomed: Softening growth prospects
Redeye sees slower revenue growth ahead and lowers fair value to EUR 7. 7 per share. While the company remains fundamentally unchanged, the new reality of digitalisation and social distancing will slow down brand-building and soften camera sales in the months ahead.